Hydroxylation of debrisoquine using perfused liver isolated from Sprague Dawley and DA rats: comparison with in-vivo results
- PMID: 2907535
Hydroxylation of debrisoquine using perfused liver isolated from Sprague Dawley and DA rats: comparison with in-vivo results
Abstract
The hydroxylation of debrisoquine was investigated in Sprague-Dawley (SD) and Dark-Agouti (DA) rats. Female and male rats were phenotyped in-vivo with debrisoquine six times during their growth. The ratios debrisoquine/4-hydroxydebrisoquine of the female DA rats increased until the 15th week and then decreased; but the values of the metabolic ratios never exceeded 2. Female DA rats cannot be considered as genetically deficient for hydroxylation of debrisoquine in regard to the metabolic ratio, but the percentage of debrisoquine excretion is up to ten fold higher than that in the other strains. Therefore SD and DA rat livers were perfused for 2 h when the clearance of debrisoquine was significantly lower in the female DA group than in the other groups. 4-Hydroxydebrisoquine in the perfusate increased with time, but the amount after 120 min was 12 fold lower in the female DA rat group than in the female SD rat group. The results of the male DA group fell between. This study confirms that female DA rats present a lower debrisoquine 4-hydroxylating capacity than other rats but shows that urinary metabolic ratio is not sufficient to assess the deficiency of debrisoquine hydroxylation.
Similar articles
-
Interstrain comparison of hepatic and renal microsomal carcinogen metabolism and liver S9-mediated mutagenicity in DA and Lewis rats phenotyped as poor and extensive metabolizers of debrisoquine.Drug Metab Dispos. 1986 Jan-Feb;14(1):118-26. Drug Metab Dispos. 1986. PMID: 2868854
-
Defective bile acid transport in an animal model of defective debrisoquine hydroxylation.Biochem Pharmacol. 1986 Mar 1;35(5):753-9. doi: 10.1016/0006-2952(86)90242-x. Biochem Pharmacol. 1986. PMID: 3954785
-
Polymorphic ochratoxin A hydroxylation in rat strains phenotyped as poor and extensive metabolizers of debrisoquine.Xenobiotica. 1989 Feb;19(2):225-30. doi: 10.3109/00498258909034695. Xenobiotica. 1989. PMID: 2786290
-
Selective in vivo inhibition by quinidine of methoxyphenamine oxidation in rat models of human debrisoquine polymorphism.Xenobiotica. 1989 Feb;19(2):189-97. doi: 10.3109/00498258909034691. Xenobiotica. 1989. PMID: 2786289
-
Inhibition of desipramine 2-hydroxylation by quinidine and quinine in rapid and slow debrisoquine hydroxylators.Psychopharmacol Ser. 1989;7:201-5. doi: 10.1007/978-3-642-74430-3_21. Psychopharmacol Ser. 1989. PMID: 2687858 Review. No abstract available.
Cited by
-
Effects of MDMA on blood glucose levels and brain glucose metabolism.Eur J Nucl Med Mol Imaging. 2007 Jun;34(6):916-25. doi: 10.1007/s00259-006-0262-8. Epub 2007 Jan 12. Eur J Nucl Med Mol Imaging. 2007. PMID: 17219137
-
The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype.Br J Pharmacol. 1995 Aug;115(7):1281-9. doi: 10.1111/j.1476-5381.1995.tb15037.x. Br J Pharmacol. 1995. PMID: 7582557 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources